Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Once-weekly fluoxetine.

A J Wagstaff1, K L Goa

  • 1Adis International Limited, Auckland, New Zealand. demail@adis.co.nz

Drugs
|January 5, 2002
PubMed
Summary
This summary is machine-generated.

A new once-weekly fluoxetine formulation demonstrates comparable efficacy and relapse prevention to daily dosing. This delayed-release option also shows improved patient compliance and similar tolerability.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Velnacrine in Alzheimer's Disease : An Initial Appraisal of its Clinical Potential.

CNS drugs·2016
Same author

Is female sex a risk factor for stroke and thromboembolism in patients with atrial fibrillation? A systematic review and meta-analysis.

QJM : monthly journal of the Association of Physicians·2014
Same author

No lasting legacy: no change in reporting of women's sports in the British print media with the London 2012 Olympics and Paralympics.

Journal of public health (Oxford, England)·2014
Same author

Paroxetine : a review of its pharmacology and therapeutic potential in the management of panic disorder.

CNS drugs·2013
Same author

Adjuvanted influenza vaccine.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2007
Same author

Liposomal influenza vaccine.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2007
Same journal

Botulinum Toxin Type A for Trigeminal and Postherpetic Neuralgia: An Umbrella Review of Systematic Reviews.

Drugs·2026
Same journal

Biologics and Small Molecule Inhibitors: Novel Therapeutic Strategies for Cutaneous Adverse Drug Reactions.

Drugs·2026
Same journal

Use of Sedative-Hypnotic Drugs and the Risk of Developing Alzheimer's Disease: A Systematic Review, Meta-Analysis and Meta-Regression.

Drugs·2026
Same journal

Relacorilant: First Approval.

Drugs·2026
Same journal

Developmental Progress and Future Potential for Inhaled Biologics in the Treatment of Respiratory Diseases.

Drugs·2026
Same journal

Linerixibat: First Approval.

Drugs·2026
See all related articles

Area of Science:

  • Pharmacology
  • Psychiatry
  • Clinical Pharmacy

Background:

  • Selective serotonin reuptake inhibitors (SSRIs) like fluoxetine are mainstays in depression treatment.
  • Fluoxetine's long half-life enables alternative dosing strategies.
  • Delayed-release formulations can improve patient adherence and therapeutic outcomes.

Purpose of the Study:

  • To evaluate the efficacy and tolerability of a novel once-weekly, delayed-release fluoxetine 90 mg formulation.
  • To compare relapse rates between once-weekly fluoxetine, daily fluoxetine, and placebo.
  • To assess patient compliance with the once-weekly formulation versus daily dosing.

Main Methods:

  • A randomized controlled trial comparing once-weekly fluoxetine 90 mg, daily fluoxetine 20 mg, and placebo.

Related Experiment Videos

  • Patients initially responded to 13 weeks of daily fluoxetine 20 mg.
  • Efficacy assessed via relapse rates, modified 17-item Hamilton Rating Scale for Depression, and Clinical Global Impressions - Severity of Illness Scale.
  • Compliance monitored electronically.

    • Main Results:

    • Once-weekly fluoxetine 90 mg showed similar cumulative relapse rates to daily fluoxetine 20 mg and significantly lower rates than placebo.
    • Efficacy measures were comparable between once-weekly and daily fluoxetine formulations.
    • Patient compliance was significantly higher with the once-weekly formulation (87.5%) compared to daily dosing (79.4%).
    • Tolerability profiles were similar across all treatment groups.

    Conclusions:

    • Once-weekly delayed-release fluoxetine 90 mg is an effective and well-tolerated alternative to daily dosing for depression.
    • This formulation offers a potential strategy to improve patient compliance in long-term treatment.
    • The findings support the use of once-weekly fluoxetine for sustained depression management.